Replimune Group Inc (REPL)

$14.97 -0.22 (-1.45%)
Market Cap 1.28B
Revenue (ttm) 0.00
Net Income (ttm) -313.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.50
Volume 2,398,200
Avg Vol 5,441,224
Day's Range N/A - N/A
Shares Out 84.03M
Stochastic %K 91%
Beta 0.88
Analysts Strong Sell
Price Target $19.33

Company Profile

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The c...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 222 9600
Address:
500 Unicorn Park Drive, Suite 303, 3rd Floor, Woburn, United States
Hotresearchsgoldenage
Hotresearchsgoldenage Aug. 14 at 9:39 PM
$REPL we have a 12,month runway but going to dilute investors anyway .
2 · Reply
Hotresearchsgoldenage
Hotresearchsgoldenage Aug. 14 at 9:32 PM
$REPL another offering so soon ?
0 · Reply
beachsidefreddy
beachsidefreddy Aug. 14 at 9:26 PM
$REPL pumpers deserved this its a scam
0 · Reply
TwongStocks
TwongStocks Aug. 14 at 8:24 PM
$REPL 10-Q filed https://www.sec.gov/ix?doc=/Archives/edgar/data/1737953/000162828026057099/repl-20260630.htm • Shares outstanding as of August 11, 2026 was 94,219,634
0 · Reply
LENM2000
LENM2000 Aug. 14 at 8:06 PM
$REPL Took my 'L' on the downside with this stock. Moving on. Congratulations longs!
0 · Reply
beachsidefreddy
beachsidefreddy Aug. 14 at 8:03 PM
$REPL just for the record I have two stocks both big positions LUNG AND IOVA look at both of them today while you pumpers were in this piece of shit
0 · Reply
beachsidefreddy
beachsidefreddy Aug. 14 at 7:38 PM
$REPL I told you pumpers it was 100% going under $15
2 · Reply
Nathan82
Nathan82 Aug. 14 at 7:15 PM
$REPL Volume is like 10% of the 10 day average, price will just stagnate for now.
0 · Reply
beachsidefreddy
beachsidefreddy Aug. 14 at 6:52 PM
$REPL pumpers your screwed
0 · Reply
beachsidefreddy
beachsidefreddy Aug. 14 at 5:37 PM
$REPL truth: I just covered my short not because I wanted to. I made a little but I was being held at 300% at Robin Hood my LUNG IS GOING NUTS AND I WANTED TO BUY MORE AND I CAN’T BECAUSE I’M BEING HELD AT 300% ON REPL WILL SHORT AGAIN BEFORE NEXT FRIDAY MASSSACRE OPTIONS
0 · Reply
Latest News on REPL
Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

Aug 14, 2026, 8:00 AM EDT - 12 hours ago

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

Replimune Group Earnings release: Q1 2027

Aug 14, 2026, 7:00 AM EDT - 13 hours ago

Replimune Group Earnings release: Q1 2027

Replimune Group Quarterly report: Q1 2027

Aug 14, 2026, 7:00 AM EDT - 13 hours ago

Replimune Group Quarterly report: Q1 2027

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL

Aug 13, 2026, 12:37 PM EDT - 1 day ago

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL

Replimune Announces Pricing of $150 Million Underwritten Offering

Aug 10, 2026, 8:00 AM EDT - 4 days ago

Replimune Announces Pricing of $150 Million Underwritten Offering

Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling.

Aug 7, 2026, 12:36 PM EDT - 7 days ago

Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling.

Replimune price target raised to $20 from $16 at BMO Capital

2026-08-07T12:02:14.000Z - 7 days ago

Replimune price target raised to $20 from $16 at BMO Capital

Wedbush upgrades Replimune to Outperform following FDA decision

2026-08-07T10:31:49.000Z - 7 days ago

Wedbush upgrades Replimune to Outperform following FDA decision

Replimune upgraded to Outperform from Neutral at Wedbush

2026-08-07T10:27:08.000Z - 7 days ago

Replimune upgraded to Outperform from Neutral at Wedbush

Replimune announces FDA accelerated approval of Tudriqev for advanced melanoma

2026-08-06T21:50:37.000Z - 8 days ago

Replimune announces FDA accelerated approval of Tudriqev for advanced melanoma

Replimune Group Press release: FDA announcement

Aug 6, 2026, 4:30 PM EDT - 8 days ago

Replimune Group Press release: FDA announcement

Replimune Group Slides: FDA announcement

Aug 6, 2026, 4:30 PM EDT - 8 days ago

Replimune Group Slides: FDA announcement

US FDA approves Replimune's skin cancer drug

Aug 6, 2026, 4:26 PM EDT - 8 days ago

US FDA approves Replimune's skin cancer drug

FDA Approves Replimune's Melanoma Drug On Third Attempt

Aug 6, 2026, 4:18 PM EDT - 8 days ago

FDA Approves Replimune's Melanoma Drug On Third Attempt

Replimune upgraded to Outperform from Market Perform at Leerink

2026-08-04T09:05:14.000Z - 10 days ago

Replimune upgraded to Outperform from Market Perform at Leerink

Why Is Replimune (REPL) Stock Up Today?

2026-07-31T15:36:59.000Z - 14 days ago

Why Is Replimune (REPL) Stock Up Today?

Piper upgrades Replimune to Overweight on better odds of RP1 approval

2026-07-31T12:51:02.000Z - 14 days ago

Piper upgrades Replimune to Overweight on better odds of RP1 approval

Replimune upgraded to Overweight from Neutral at Piper Sandler

2026-07-31T12:45:48.000Z - 14 days ago

Replimune upgraded to Overweight from Neutral at Piper Sandler

This Biotech Stock Is Soaring 132% After Key FDA Panel Vote on Skin Cancer Treatment

Jul 31, 2026, 8:37 AM EDT - 14 days ago

This Biotech Stock Is Soaring 132% After Key FDA Panel Vote on Skin Cancer Treatment

Replimune price target raised to $12 from $9 at Wedbush

2026-07-31T12:25:20.000Z - 14 days ago

Replimune price target raised to $12 from $9 at Wedbush

Why is Biotech Stock Replimune (REPL) Soaring Over 120% Today?

2026-07-31T10:31:14.000Z - 14 days ago

Why is Biotech Stock Replimune (REPL) Soaring Over 120% Today?

BMY

Replimune surges after FDA advisers back skin cancer drug

Jul 31, 2026, 5:40 AM EDT - 14 days ago

Replimune surges after FDA advisers back skin cancer drug

Replimune upgraded to Overweight from Neutral at Cantor Fitzgerald

2026-07-31T08:55:19.000Z - 14 days ago

Replimune upgraded to Overweight from Neutral at Cantor Fitzgerald

Replimune confirms FDA AdCom voted in favor of experimental melanoma treatment

2026-07-30T22:20:25.000Z - 15 days ago

Replimune confirms FDA AdCom voted in favor of experimental melanoma treatment

Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma

Jul 30, 2026, 6:15 PM EDT - 15 days ago

Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma

FDA panel votes 10-3 in favor of Replimune’s experimental melanoma treatment

2026-07-30T21:45:26.000Z - 15 days ago

FDA panel votes 10-3 in favor of Replimune’s experimental melanoma treatment

A Food and Drug Administration advisory panel voted 10-3 for Replimune Group's experimental melanoma therapy, after experts raised doubts about whether the company's data and trial design could be trusted to show the drug works

Jul 30, 2026, 5:27 PM EDT - 15 days ago

A Food and Drug Administration advisory panel voted 10-3 for Replimune Group's experimental melanoma therapy, after experts raised doubts about whether the company's data and trial design could be trusted to show the drug works

US FDA panel backs Replimune skin cancer drug study data

Jul 30, 2026, 5:10 PM EDT - 15 days ago

US FDA panel backs Replimune skin cancer drug study data

Replimune Group Slides: Investor presentation

Jul 30, 2026, 7:00 AM EDT - 15 days ago

Replimune Group Slides: Investor presentation

Replimune Group Proxy statement: Proxy filing

Jul 29, 2026, 8:00 AM EDT - 16 days ago

Replimune Group Proxy statement: Proxy filing

Replimune Group Proxy statement: Proxy filing

Jul 29, 2026, 8:00 AM EDT - 16 days ago

Replimune Group Proxy statement: Proxy filing

Replimune Group, Inc. (REPL) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel Following FDA Briefing Document

Jul 28, 2026, 6:21 PM EDT - 17 days ago

Replimune Group, Inc. (REPL) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel Following FDA Briefing Document

US FDA staff raise efficacy concerns on Replimune's skin cancer drug ahead of meeting

Jul 28, 2026, 7:47 AM EDT - 17 days ago

US FDA staff raise efficacy concerns on Replimune's skin cancer drug ahead of meeting

Replimune Group Registration statement: Registration filing

Jul 24, 2026, 8:00 AM EDT - 21 days ago

Replimune Group Registration statement: Registration filing

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Replimune Group, Inc. (REPL)

Jul 15, 2026, 11:28 AM EDT - 4 weeks ago

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Replimune Group, Inc. (REPL)

Replimune Group Proxy statement: Proxy filing

Jul 13, 2026, 8:00 AM EDT - 4 weeks ago

Replimune Group Proxy statement: Proxy filing

Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update

Jun 29, 2026, 8:00 AM EDT - 6 weeks ago

Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update

Replimune Group Earnings release: Q4 2026

Jun 29, 2026, 8:00 AM EDT - 6 weeks ago

Replimune Group Earnings release: Q4 2026

Replimune Group Annual report: Q4 2026

Jun 29, 2026, 8:00 AM EDT - 6 weeks ago

Replimune Group Annual report: Q4 2026

Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma

Jun 26, 2026, 8:00 AM EDT - 7 weeks ago

Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

May 31, 2026, 8:00 AM EDT - 2 months ago

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

May 30, 2026, 8:00 AM EDT - 2 months ago

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

How Replimune's drug got a third chance after the White House intervened

May 29, 2026, 9:53 PM EDT - 2 months ago

How Replimune's drug got a third chance after the White House intervened

Replimune to resubmit twice-rejected drug for approval after FDA shakeup

May 29, 2026, 8:51 AM EDT - 2 months ago

Replimune to resubmit twice-rejected drug for approval after FDA shakeup

Replimune reaches agreement with US FDA to resubmit melanoma drug application

May 29, 2026, 8:07 AM EDT - 2 months ago

Replimune reaches agreement with US FDA to resubmit melanoma drug application

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

May 29, 2026, 8:00 AM EDT - 2 months ago

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

Replimune Gets Third Try at FDA Approval After Makary Departure

May 29, 2026, 7:30 AM EDT - 2 months ago

Replimune Gets Third Try at FDA Approval After Makary Departure

FDA Commissioner Makary defends agency's decision on Replimune's drug

May 5, 2026, 10:58 AM EDT - 3 months ago

FDA Commissioner Makary defends agency's decision on Replimune's drug

US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejection

Apr 22, 2026, 12:56 PM EDT - 4 months ago

US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejection

Replimune co-founder calls FDA rejection of melanoma drug ‘unfair'

Apr 13, 2026, 11:46 AM EDT - 4 months ago

Replimune co-founder calls FDA rejection of melanoma drug ‘unfair'

Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

Apr 10, 2026, 5:02 PM EDT - 4 months ago

Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

US FDA declines to approve Replimune's drug for advanced skin cancer

Apr 10, 2026, 11:24 AM EDT - 4 months ago

US FDA declines to approve Replimune's drug for advanced skin cancer

Replimune Group Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 2:20 PM EDT - 5 months ago

Replimune Group Transcript: Leerink Global Healthcare Conference 2026

Replimune to Present at Two Upcoming Investor Conferences

Mar 2, 2026, 8:00 AM EST - 5 months ago

Replimune to Present at Two Upcoming Investor Conferences

Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

Feb 3, 2026, 8:00 AM EST - 6 months ago

Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

Replimune Group Quarterly report: Q3 2026

Feb 3, 2026, 8:00 AM EST - 6 months ago

Replimune Group Quarterly report: Q3 2026

Replimune Group Earnings release: Q3 2026

Feb 3, 2026, 8:00 AM EST - 6 months ago

Replimune Group Earnings release: Q3 2026

Replimune Group Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 4:30 PM EST - 7 months ago

Replimune Group Transcript: 44th Annual J.P. Morgan Healthcare Conference

Replimune Group Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 4:30 PM EST - 7 months ago

Replimune Group Slides: 44th Annual J.P. Morgan Healthcare Conference

Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 8:00 AM EST - 8 months ago

Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference

Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)

Nov 7, 2025, 4:45 PM EST - 10 months ago

Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)

Replimune Group Earnings release: Q2 2026

Nov 6, 2025, 8:30 AM EST - 10 months ago

Replimune Group Earnings release: Q2 2026

Replimune Group Quarterly report: Q2 2026

Nov 6, 2025, 8:30 AM EST - 10 months ago

Replimune Group Quarterly report: Q2 2026

Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update

Nov 6, 2025, 8:00 AM EST - 10 months ago

Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update

Replimune Group Registration statement: Registration Filing

Nov 6, 2025, 7:00 AM EST - 10 months ago

Replimune Group Registration statement: Registration Filing

Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma

Oct 20, 2025, 7:00 AM EDT - 10 months ago

Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

Oct 19, 2025, 8:00 AM EDT - 10 months ago

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

Replimune Provides Update Following Type A Meeting with FDA

Sep 18, 2025, 9:15 AM EDT - 11 months ago

Replimune Provides Update Following Type A Meeting with FDA

Hotresearchsgoldenage
Hotresearchsgoldenage Aug. 14 at 9:39 PM
$REPL we have a 12,month runway but going to dilute investors anyway .
2 · Reply
Hotresearchsgoldenage
Hotresearchsgoldenage Aug. 14 at 9:32 PM
$REPL another offering so soon ?
0 · Reply
beachsidefreddy
beachsidefreddy Aug. 14 at 9:26 PM
$REPL pumpers deserved this its a scam
0 · Reply
TwongStocks
TwongStocks Aug. 14 at 8:24 PM
$REPL 10-Q filed https://www.sec.gov/ix?doc=/Archives/edgar/data/1737953/000162828026057099/repl-20260630.htm • Shares outstanding as of August 11, 2026 was 94,219,634
0 · Reply
LENM2000
LENM2000 Aug. 14 at 8:06 PM
$REPL Took my 'L' on the downside with this stock. Moving on. Congratulations longs!
0 · Reply
beachsidefreddy
beachsidefreddy Aug. 14 at 8:03 PM
$REPL just for the record I have two stocks both big positions LUNG AND IOVA look at both of them today while you pumpers were in this piece of shit
0 · Reply
beachsidefreddy
beachsidefreddy Aug. 14 at 7:38 PM
$REPL I told you pumpers it was 100% going under $15
2 · Reply
Nathan82
Nathan82 Aug. 14 at 7:15 PM
$REPL Volume is like 10% of the 10 day average, price will just stagnate for now.
0 · Reply
beachsidefreddy
beachsidefreddy Aug. 14 at 6:52 PM
$REPL pumpers your screwed
0 · Reply
beachsidefreddy
beachsidefreddy Aug. 14 at 5:37 PM
$REPL truth: I just covered my short not because I wanted to. I made a little but I was being held at 300% at Robin Hood my LUNG IS GOING NUTS AND I WANTED TO BUY MORE AND I CAN’T BECAUSE I’M BEING HELD AT 300% ON REPL WILL SHORT AGAIN BEFORE NEXT FRIDAY MASSSACRE OPTIONS
0 · Reply
beachsidefreddy
beachsidefreddy Aug. 14 at 5:02 PM
$REPL what do you think those pumpers who bought it at 6.35 are doing now?
1 · Reply
beachsidefreddy
beachsidefreddy Aug. 14 at 4:45 PM
$REPL $14 incoming!!
0 · Reply
beachsidefreddy
beachsidefreddy Aug. 14 at 4:43 PM
$REPL PUMPERS PADDLE HARDER!!
0 · Reply
bph082672
bph082672 Aug. 14 at 4:13 PM
$REPL This should be dropping hard
0 · Reply
bph082672
bph082672 Aug. 14 at 4:12 PM
$REPL What is the MM doing here???
0 · Reply
beachsidefreddy
beachsidefreddy Aug. 14 at 3:37 PM
$REPL MM have this under $15 at 4 pm
2 · Reply
beachsidefreddy
beachsidefreddy Aug. 14 at 3:19 PM
$REPL that 19,000 block biggest yet was a short
0 · Reply
beachsidefreddy
beachsidefreddy Aug. 14 at 3:06 PM
$REPL PUMPERS PADDLE HARDER YOUR GOING DOWNSTREAM !!
0 · Reply
beachsidefreddy
beachsidefreddy Aug. 14 at 1:56 PM
$REPL anyone who thinks this isn’t going under 15 x 4 o’clock, has no clue about Option expiration
0 · Reply
OGHEDGEFUNDIE
OGHEDGEFUNDIE Aug. 14 at 1:52 PM
$REPL 🚀🌕
0 · Reply
beachsidefreddy
beachsidefreddy Aug. 14 at 1:47 PM
$REPL NEW LOW OF DAY!!
0 · Reply
beachsidefreddy
beachsidefreddy Aug. 14 at 1:36 PM
$REPL “DOWN GOES FRAZIER….DOWN GOES FRAZIER” !!!!!
2 · Reply